Publications by authors named "Pascal Espie"

Claim this Profile
E
Efficacy and safety of iscalimab, a novel anti-CD40 monoclonal antibody, in moderate-to-severe myasthenia gravis: A phase 2 randomized study.
Baltazar GomezMancilla, Matthew N Meriggioli, Angela Genge, Ronenn Roubenoff, Pascal Espié

J Clin Neurosci· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immunosuppression Profile of CFZ533 (Iscalimab), a Non-Depleting Anti-CD40 Antibody, and the Presence of Opportunistic Infections in a Rhesus Monkey Toxicology Study.
Thierry D Flandre, Keith G Mansfield, Pascal J Espié, Tina Rubic-Schneider, Peter Ulrich

Toxicol Pathol· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Novel Anti-CD40 Monoclonal Antibody, Iscalimab, for Control of Graves Hyperthyroidism-A Proof-of-Concept Trial.
George J Kahaly, Marius Nicolae Stan, Lara Frommer, Peter Gergely, Laurence Colin, Pascal Espie

J Clin Endocrinol Metab· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of the anti-CD40 antibody iscalimab in patients with primary Sjögren's syndrome: a multicentre, randomised, double-blind, placebo-controlled, proof-of-concept study.
Benjamin A Fisher, Antonia Szanto, Wan-Fai Ng, Michele Bombardieri, Maximilian G Posch

Lancet Rheumatol· March 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-in-human clinical trial to assess pharmacokinetics, pharmacodynamics, safety, and tolerability of iscalimab, an anti-CD40 monoclonal antibody.
Pascal Espié, YanLing He, Phillip Koo, Denise Sickert, Cyrielle Dupuy

Am J Transplant· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterization of the in vitro and in vivo properties of CFZ533, a blocking and non-depleting anti-CD40 monoclonal antibody.
Jacinda Ristov, Pascal Espie, Peter Ulrich, Denise Sickert, Thierry Flandre

Am J Transplant· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nonclinical Safety Assessment of CFZ533, a Fc-Silent Anti-CD40 Antibody, in Cynomolgus Monkeys.
Peter Ulrich, Thierry Flandre, Pascal Espie, Denise Sickert, Tina Rubic-Schneider

Toxicol Sci· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Physiologically based pharmacokinetics (PBPK).
Pascal Espié, Dominique Tytgat, Maria-Laura Sargentini-Maier, Italo Poggesi, Jean-Baptiste Watelet

Drug Metab Rev· December 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gender and interindividual variability in pharmacokinetics.
Jean-Marie Nicolas, Pascal Espie, Mathieu Molimard

Drug Metab Rev· December 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and metabolism of 14C-brivaracetam, a novel SV2A ligand, in healthy subjects.
Maria Laura Sargentini-Maier, Pascal Espié, Alain Coquette, Armel Stockis

Drug Metab Dispos· January 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis